2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 195

Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Abstract Number: 2378

Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Abstract Number: 615

Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Abstract Number: 1642

Pharmacokinetic-Pharmacodynamic Analysis of GS-4059-Mediated Bruton’s Tyrosine Kinase Inhibition
Abstract Number: 1645

Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of ASP5094, an Anti-Alpha-9-Integrin Monoclonal Antibody, Following Single Intravenous Doses in Healthy Subjects
Abstract Number: 756

Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
Abstract Number: 1634

Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Abstract Number: 1629

Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials
Abstract Number: 1620

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MEDI4920, a Novel, Engineered CD40 Ligand Antagonist, in Healthy Volunteers
Abstract Number: 194

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Abstract Number: 191

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
Abstract Number: 190

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Abstract Number: 193

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Abstract Number: 388

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Abstract Number: 1695

Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].